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Abstract
Objective The objective of this study is to assess the HPV
vaccination coverage of 11–19-year-old girls during a
state-coordinated HPV vaccination program in Geneva,
Switzerland, from September 2008 to June 2011.
Methods State Medical Office coordinated the HPV vacci-
nation program. Each service provider transmitted the list of
the persons who had received their first, second, or third shot.
Results The global coverage rates, 3 years after the program
had been launched, were 63.72% for one dose, 63.22% for two
doses, and 61.40% for three doses of the HPV vaccine.
Conclusion This study shows that it is possible to obtain
a good coverage rates after 3 years of a state-coordinated
HPV vaccination program.
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Introduction
The human papilloma virus (HPV) is the most frequent cause
of sexually transmitted infections in Switzerland (OFSP
2008a). The HPV is responsible, exclusively or not, for a large
number of pathologies: cervical carcinoma in situ or invasive
(100% of the cases), cancers of the anus (90%), cancers of the
penis (40%), cancers of the vulva and the vagina (40%), and
genital condylomas (100%). There are more than 120 geno-
types of HPV. HPV 16 and 18 are directly responsible for the
majority of the cervical cancers, HPV 6 and 11 for the con-
dylomas. These viruses are widespread and the infection,
which generally goes unnoticed, can be transmitted during the
first sexual intercourse. Cancers may develop 15–20 years
after infection (OFSP 2008a, b; WHO 2005).
Cervical cancer is a major public health problem. It
affects approximately 1.4 million persons worldwide, with
an annual incidence of 500,000 cases (Simoens et al. 2009;
WHO 2005). Worldwide, it is responsible for 274,000
deaths per year. Cervical cancer is the second cause of
cancer for women in the world just after breast cancer
(Wong et al. 2011). In Europe, cervical cancer affects
approximately 60,000 women and is responsible for 30,000
deaths every year (Simoens et al. 2009).
In Switzerland, every year, 5,000 young women present
a precancerous lesion of the cervix or an in situ carcinoma
and 320 an invasive cervical carcinoma requiring a surgi-
cal/laser treatment. Half of the women presenting a
precancerous lesion of the cervix or an in situ carcinoma is
less than 50 years old when the disease is diagnosed.
In Geneva, there are approximately 400 cases of in situ
and 30 invasive cervix cancers every year, resulting in
5–10 deaths per year (RGT 2009).
The first vaccine to prevent cervical cancer and pre-
cancerous genital lesions caused by human papilloma virus
(Gardasil) was approved by the Swiss Drug Regulation
Agency in 2006. To be completely effective, three vaccine
doses are recommended within 6 months and should be
administered before the beginning of sexual activity.
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The aim of this study was to assess the HPV coverage
among 11–19-year-old girls (aged at the beginning of the
program, in September 2008) in the Swiss canton of
Geneva.
Methods
The HPV vaccination program in Geneva
The Swiss Federal Vaccination Committee recommended
HPV vaccination free of charge for girls, aged 11 to 19
(OFSP 2008b), if in the context of a ‘‘state vaccination
program.’’ This free of charge for the girls stopped after
their 20th birthday.
The objective of the program was to make three doses of
the vaccine available as easily as possible to 11–19-year-
old female residents of the state of Geneva (eligible cri-
teria) in order to reach the highest possible coverage.
The State Medical Office coordinated the Geneva HPV
vaccination program. It relied on practitioners in private
practice (especially pediatricians, gynecologists, internists,
and general practitioners), the School Health Service
(Service Sante´ de la Jeunesse, SSJ) and a specially estab-
lished temporary vaccination structure at the Geneva
University Hospital (HUG). Vaccines were made available
to the physicians through the State Medical Office.
The promotion of this vaccination program for the
practitioners and the public was jointly implemented by the
State Medical Office health, the Geneva University Hos-
pital and School Health Service via two sites of
information especially developed for this purpose (http://
ge.ch/dares/maladies-transmissibles/vaccination_hpv-1030-
3374.html and http://www.hpv-hug.ch/). A series of infor-
mation brochures was realized and distributed to the
healthcare professionals of the canton and in public
schools. The eligible girls received directly, in their place
of residence, a letter containing their three vouchers of
vaccinations for the first, second, and third shots of vac-
cines. They could then choose their dealing doctors or the
HUG vaccination structure. In these two cases, the
vouchers of vaccinations were transmitted to the State
Medical Office to monitor the program. A system of follow
up by SMS and letter was set up to remind them of the
second and third shots of vaccine.
Target population
The target population to be vaccinated was defined by the
state authorities as the 11–19-year-old girls living in the
canton of Geneva. At the beginning of the program in
September 2008, approximately 24,000 girls were poten-
tially eligible, with a new cohort each year of
approximately 2,400 girls (data obtained from the state
population registry of the Geneva State).
Epidemiological monitoring
Each service provider transmitted quarterly to the State
Medical Office the anonymous list of the persons who had
received their first, second, and third shots. The statistical
analysis of the collected data was totally anonymous. The
data were processed through the Te´le´form software and
analyzed to assess the HPV coverage of the target popula-
tion. The data collected before June 30, 2011 was included
into the study. Descriptive statistical methods with the Stata
10 software (StataCorp 2007) were used. Confidence inter-
vals and inferential statistics were not calculated because the
studied population was considered exhaustive.
Results
The global coverage rates as of June 30, 2011 for the target
population (1989–1997-born cohorts, 11–19-years old on
September 2008, being 14–22-years old on June 2011)
were 63.72% for one dose, 63.22% for two doses and
61.4% for three doses of the HPV vaccine. These rates
were quite different from one cohort to another. For
example, for girls born in 1994 or 1995 (16–17-years old
on 30 June 2011), cover rates were 78.5 and 80.3%,
respectively for the first dose, 78.2 and 79.5% for second
dose, and 78 and 79.2% for the third dose (Table 1).
The contribution to the vaccination program of the three
service providers varied according to the age of the target
population (Fig. 1). Service providers covered different age
groups. The School Health Service (SSJ) inoculated 70% of
the 16-year-old ones, 53% of the 15-year-old ones, and less
than 10% of the 19–22 year-old ones. Medical doctors in
private practice inoculated 50–60% of the target population
except in the 15–16-year-old age group. The HUG (ad hoc
vaccination center) inoculated around 50% of the older ones
(age group 21–22 years) and a much lower proportion
(5–15%) of the younger ones (age group 13–16 years).
The proportion of eligible girls who did not attend the
second and/or third dose after receiving the first one was
similar for all age groups regardless of the service pro-
viders, with the exception of the SSJ.
Discussion
Adherence is crucial for the effectiveness of a public health
program. Effectiveness of an immunization program
depends on high coverage and strong compliance (Rouzier
and Giordanella 2010). The results of our study show that
630 E. Jeannot et al.
123
the girls who were eligible at the beginning of the program
have a cover rate of 63.72% for one dose, 65.10% for two
doses, and 61.4% for three doses.
The lower rates of vaccination for the older cohorts
(1989) might be explained by several elements: they were
less targeted by HPV vaccine promotion campaigns; they
had limited access to free vaccination: indeed vaccination
was free of charge only up to the 20th birthday and they
may not have yet a gynecologist and no longer a
pediatrician.
The vaccination patterns according to the service pro-
vider show important variations that are most likely due to
the implementation of the program as well as ‘‘consumer’’
habits: The School Health Service has inoculated a
majority of seventh graders (12–13-year-old ones) because
this is the main target population. The SSJ had introduced
vaccination as early as the school year 2007–2008, thus
technically before the official launch of the vaccination
program. Medical doctors in private practice play an
important role, having roughly vaccinated 50% of the tar-
get population and up to 65% in certain age groups: this
might reflect the special place that practitioners have as
family doctors. The HUG inoculated mostly older girls (up
to roughly 50% in the 21–22-year-old group): this might
reflect ‘‘an aspiration to some independence’’, since the
HUG vaccination unit was less family-oriented than the
practitioners and less school related than the SSJ.
There are published data on HPV vaccine coverage in
areas where the vaccine was introduced. A study led in North
Carolina among girls from 9 to 17 years shows cover rates of
39.7% for the first dose, 34.6% for the second, and 25.7% for
the third (CDC 2008). Another study from the USA reports
an HPV vaccine coverage of 44.2% for the first dose, 32.3%
for the second, and 23.5% for the third among 13–17-year-
old girls (Berry-Caban and Buenaventura 2009). An article
from England reports coverage rates among 12–13-year-old
girls for three doses of up to 80% (Canfell 2010). Italy reports
coverage rates for girls born in 1996 and 1997: 80% for the
first dose, 75% for the second, and more than 60% for the
third. A recent article shows that coverage rates among
13–17 years in USA are 53% for three doses (national
immunization survey) (Dorell et al. 2011).
Success of vaccination programs depends on a number
of elements, including, presence of qualified health experts,
availability of the vaccine, its price, the acceptability of the
vaccine in the population, a clear promotion strategy,
political support, etc. (Smith et al. 2011). The program
initiated in Geneva by the State Medical Office has bene-
fited from such a broad approach and gave promising
results, yet the effort must be kept up. Indeed one of the
key to the success of this program was the participation of
the School Health Service for effective promotion of the
vaccine combined with the implication of private physi-
cians and a specially set up vaccination center. Bradin
et al. have also demonstrated the importance and the
Table 1 Percentage dose one, two, and three for vaccinated girls born between 1989 and 1997 on June 30, 2011 at Geneva, Switzerland
Birth cohorts Age (years) on
June 30 2011
Number of
eligible girls (n)
Vaccinated girls
first dose (%)
Vaccinated girls
second dose (%)
Vaccinated girls
third dose (%)
1989 22 2,282 42.60 41.30 40.90
1990 21 2,421 52.80 51.90 51.80
1991 20 2,342 63.50 63.00 62.60
1992 19 2,256 68.10 68.90 54.50
1993 18 2,297 75.60 75.30 74.90
1994 17 2,228 78.50 78.20 78.00
1995 16 2,307 80.30 79.50 79.20
1996 15 2,218 79.30 79.00 78.10
1997 14 2,190 65.90 65.10 64.70
Total 1989–1997
(target population)
22,693 63.72 63.22 61.40
Fig. 1 Repartition of vaccination by service provider according to
age (years) on June 30, 2011 at Geneva, Switzerland
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effectiveness of school-based vaccine delivery (Brabin
et al. 2008). Coverage data from Australia, where the
vaccine policy is also based on school delivery, are very
high, which calls for advocating such a strategy (Brother-
ton et al. 2008). The possibility for the population to
choose the vaccine inoculators (doctor, HUG, or SSJ)
seems to be one of the success key of the immunization’s
program in the state of Geneva.
Data from Switzerland on HPV vaccination programs in
the different cantons will soon be available. At the
moment, this study was one of the first. A study from Vaud
canton shows a coverage at 55% for the three doses for
14–20 years (Woringer 2010). The Federal Office of the
Public Health is in the process of launching an inventory of
the HPV vaccination programs implemented in the various
cantons, addressing issues such as the adopted methodol-
ogy and the obtained coverage rates: this should give an
idea of the HPV vaccination coverage at the country level.
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